Clinical trials
NETs clinical trials
Below are recruiting nets clinical trials, each written for real people, not researchers. We’re tracking 72 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05477576RecruitingPhase 3
Lu-177–treated NET patients: new drug versus standard care
This Phase 3 trial tests RYZ101 versus standard of care in people with inoperable, well-differentiated SSTR-positive GI or pancreas neuroendocrine tumors (NETs) that keep growing after Lu-177 SSA. It may help by improving tumor control after your prior targeted radiation treatment.
Phoenix, ArizonaAges 18 years+ - NCT06479811RecruitingPhase 1
Radioactive drug for advanced neuroendocrine and other cancers
This trial tests a new radioactive drug, [212Pb]VMT-Alpha-NET, that targets a protein on certain cancer cells. It is for people with specific types of advanced cancers that have gotten worse and are not responding to standard treatments.
Bethesda, MarylandAges 18–120 - NCT06427798RecruitingPhase 1/Phase 2
Radioactive drug for previously treated gut or adrenal tumors
This trial tests a new radioactive drug, [212Pb]VMT-alpha-NET, that targets a receptor found on some tumor cells. It is for people with certain gut or adrenal gland tumors that have already been treated with a similar therapy but are still growing.
Bethesda, MarylandAges 18–120 - NCT07057622RecruitingPhase 3
Comparing a new radiation therapy and long-acting medication for neuroendocrine tumors
This phase 3 trial tests a radioactive drug (177Lu-DOTATATE) against a long-acting medication (Octreotide LAR) for people with advanced neuroendocrine tumors (NETs) that have grown despite standard treatment. The study aims to see which treatment works better and is safer.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05385861Enrolling by invitationPhase 1/Phase 2
ONIVYDE plus carboplatin for advanced gut neuroendocrine cancer
This Phase 1/2 study tests ONIVYDE® (a type of irinotecan drug) combined with carboplatin in people with advanced or metastatic gastroenteropancreatic poorly differentiated neuroendocrine carcinoma. The goal is to see how well the treatment works and how safely it can be given.
Kaohsiung CityAges 20–80 - NCT07319416Recruiting
Ultrasound study for PRRT response in GEP-NET
This trial tests if a special ultrasound can help doctors see how well treatment is working for a type of slow-growing gut or pancreas cancer (GEP-NET). It may help guide your care if you are starting a therapy called PRRT (peptide receptor radionuclide therapy).
Rome, RomeAges 18 years+ - NCT05636618RecruitingPhase 1/Phase 2
Targeted radiation for certain receptor-positive tumors
This trial tests a targeted form of radiation made to stick to specific “somatostatin receptor” markers on tumors. It is designed for people with advanced, receptor-positive neuroendocrine tumors or meningioma who may have had prior treatments and need more options.
Jacksonville, FloridaAges 18–90 - NCT05997056RecruitingPhase 2
Nab-sirolimus for neuroendocrine tumors of gut, lung, or pancreas
This trial tests a new drug, nab-sirolimus, for people with certain types of neuroendocrine tumors that have spread or can't be removed by surgery. It's for those who haven't tried a similar treatment before.
Newport Beach, CaliforniaAges 18 years+ - NCT06035289Recruiting
Severe asthma registry for children and adults
This registry collects information about children and adults with severe asthma that is not well controlled with standard treatments. The goal is to better understand severe asthma and improve care.
AltdorfAges 6 years+ - NCT06402695Recruiting
Observational study on digestive and lung NETs
This study follows people with a type of tumor called a neuroendocrine tumor (NET) that started in the digestive system or lungs, to learn more about how the disease progresses and how it responds to treatment.
RomeAges 18 years+ - NCT06784752RecruitingPhase 3
Testing a targeted radiation therapy for advanced neuroendocrine tumors
This trial tests a radioactive drug called [177Lu]Lu-DOTA-TATE for people with advanced neuroendocrine tumors (GEP-NET) that have grown or spread. The drug targets tumor cells that have a specific receptor (SSTR) and delivers radiation directly to them, aiming to slow or shrink the tumors while limiting damage to healthy tissue.
Scottsdale, ArizonaAges 12–100 - NCT07165132RecruitingPhase 1
RYZ401 for advanced neuroendocrine tumors
This trial tests an experimental drug called RYZ401 for people with advanced neuroendocrine tumors (NETs) that show a certain marker on scans. The drug is designed to target the tumor cells directly and may be a new option for those who have not had a similar type of targeted radiation therapy.
Iowa City, IowaAges 18 years+ - NCT07264556Recruiting
Comparing three anesthesia types for colorectal cancer surgery
This trial compares three types of anesthesia during colorectal cancer surgery to see how they affect the body's immune response and cancer cells. It may help find the safest and most effective anesthesia option for people having this operation for the first time.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT05142384Recruiting
Online therapy program for mothers with depression symptoms
This study tests an internet-based cognitive behavioral therapy (an online skills-based talk therapy) to help mothers with depression symptoms. It’s offered through Head Start, where participating moms and their children connect with the program.
Springfield, OregonAges 2 years+ - NCT07753200RecruitingPhase 4
Comparing two blood thinners for atrial fibrillation and heart disease
This study compares two blood-thinning medicines, edoxaban and apixaban, to see which one is better at preventing strokes and bleeding in people who have both atrial fibrillation and coronary artery disease. If you're eligible, you may receive one of these standard treatments, and the trial could help find the safer option.
SeoulAges 19 years+ - NCT06541080Recruiting
CollectNET 2.0: Blood Sample Collection for Neuroendocrine Tumors
This study collects blood samples from people with neuroendocrine tumors (NENs) to build a sample bank for future research. It looks at how tumors change over time and how they respond to treatment.
Rumst, AntwerpAges 18 years+ - NCT06256705Recruiting
Study of targeted radiation for neuroendocrine tumors
This study follows people with a type of digestive tract cancer called GEP-NET that has spread and is growing. It uses a special imaging scan to find tumors that absorb a radioactive drug, then treats them with targeted radiation therapy. The goal is to learn more about who benefits most from this treatment.
ClichyAges 18 years+ - NCT05906316Recruiting
Study of new treatment plan for MAC lung infection
This study follows people with a newly diagnosed MAC lung infection (a specific type of mycobacterial disease) and tests how they do on the standard three-drug treatment plan. It may help researchers better understand outcomes and safety for this condition.
Portland, OregonAges 18 years+ - NCT05773274RecruitingPhase 2
Retreating with 177Lu-DOTATATE radiation versus usual treatment
This trial tests whether repeating a targeted radioactive treatment (177Lu-DOTATATE) works better than standard options in people with metastatic gastroenteropancreatic neuroendocrine tumors. It may help by controlling tumor growth after the first round of this therapy stops working.
Birmingham, AlabamaAges 18 years+ - NCT06505395RecruitingPhase 2
Octreotide injection for advanced neuroendocrine tumors
This trial is testing an injectable medicine called octreotide for people with advanced neuroendocrine tumors of the digestive system or pancreas. It aims to see if the medicine can help control the tumor.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06843720Recruiting
Easier cervical cancer screening study in Texas
This study tests if offering self-sampling for HPV testing makes it easier for people to get screened for cervical cancer. It is designed for patients at partner clinics in Texas who are due for screening.
Houston, TexasAges 18–65 - NCT06876831Recruiting
Lung cancer screening for current and recent smokers
This study aims to create a program to help people get screened for lung cancer while they are in the hospital. It is for people who are at higher risk due to their age and smoking history.
New York, New YorkAges 50–80 - NCT07635316Recruiting
Treatment patterns and outcomes in neuroendocrine tumors
This study examines how doctors treat gastroenteropancreatic neuroendocrine tumors (rare slow-growing cancers of the stomach, pancreas, or intestines) and how patients respond. Researchers will review medical records from 2018–2025 to understand which treatments work best and help improve care for future patients.
East Hanover, New JerseyAges 18–110 - NCT06441331RecruitingPhase 1
Lu-177 edotreotide for children with SSTR-positive tumors
This trial tests a radioactive drug called Lu-177 edotreotide for children with a certain type of tumor (SSTR-positive) that hasn't responded to other treatments. The goal is to find the right dose and see how safe it is.
San Francisco, CaliforniaAges 2–18
Hear when a new NETs trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for nets?
- Yes. Clin2 currently lists 72 recruiting nets studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a nets trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a nets trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.